Aimmune Therap (AIMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2014 | 12-2013 | |
| Cash Flows From Operating Activities | ||
| Net Income | -11,120 | -4,825 |
| Depreciation Amortization | 29 | 9 |
| Accounts payable and accrued liabilities | 206 | 208 |
| Other Working Capital | 1,237 | 283 |
| Other Operating Activity | -129 | -37 |
| Operating Cash Flow | $-9,777 | $-4,362 |
| Cash Flows From Investing Activities | ||
| PPE Investments | -56 | -69 |
| Other Investing Activity | -40 | 0 |
| Investing Cash Flow | $-96 | $-69 |
| Cash Flows From Financing Activities | ||
| Other Financing Activity | 191 | 16,164 |
| Financing Cash Flow | $191 | $16,164 |
| Beginning Cash Position | 11,951 | 218 |
| End Cash Position | 2,269 | 11,951 |
| Net Cash Flow | $-9,682 | $11,733 |
| Free Cash Flow | ||
| Operating Cash Flow | -9,777 | -4,362 |
| Capital Expenditure | -56 | -69 |
| Free Cash Flow | -9,833 | -4,431 |